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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comantithrombotic regimen was maintained throughout the whole study period (median 2
years). The primary end point was deﬁned as net clinical outcomes, a composite of
major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity
score-matching analysis was also performed in 99 patient pairs.
Results: The net clinical outcomes of the TAT group was worse than the DAPT group
(34.3% v 21.1%, p¼0.006), which was mainly driven by higher incidence of major
bleeding (16.7% vs 4.6%, p< 0.001), without any signiﬁcant increase in MACCE
(22.1% vs 17.7%, p¼0.313). In multivariate analysis, the TAT was an independent
predictor for worse net clinical outcomes (HR 1.67; 95% CI 1.09-2.57; p¼0.018) and
major bleeding (HR 3.74; 95% CI 1.74-8.02; p¼0.001). After propensity score-
matching, TAT group still had worse net clinical outcomes, mainly driven by higher
major bleeding, than DAPT group.
Conclusions: In AF patients undergoing DES implantation, prolonged administration
of TAT is associated with worse net clinical outcomes due to the substantial increase
in major bleeding without any improvement of MACCE.
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Background: Chronic kidney disease (CKD) confers increased risk for bleeding
and ischemic complications after percutaneous coronary intervention (PCI).
Guidelines recommend dual antiplatelet therapy (DAPT) in patients undergoing PCI
and anticoagulation in patients with atrial ﬁbrillation (AF) and CHADS2 scores2.
The optimal antithrombotic therapy in patients with CKD and AF after PCI is
unknown.
Methods: The AVIATOR (Antithrombotic strategy Variability In ATrial ﬁbrillation
and Obstructive coronary disease Revascularized with PCI) registry, included 859
consecutive patients with AF treated with PCI, of whom 286 had CKD (e-GFR< 60
ml/min).CKD patients were stratiﬁed in 2 groups; triple therapy (TT; warfarin plus
DAPT) or DAPT (aspirin plus clopidogrel. Major adverse cardiovascular events
(MACE) and clinically relevant bleeding (BARC2) were compared between the
groups at one year.
Results: Mean age was similar in the 2 groups (769 years). Patients receiving
TT (n¼127, 44.4%) were more often male and had higher ejection fraction
compared to patients discharged on DAPT (n¼159, 55.6%). Mean CHADS2
scores were identical between groups (3.11). MACE incidence at 1-year was
similar in the TT vs. DAPT groups (20 vs. 11%, p¼0.54) but patients on TT
tended to bleed more often (15 vs. 7%, p¼0.04). However, after adjusting for
confounding factors the association of TT with increased bleeding was attenu-
ated. (Figure)Conclusions: The most commonly prescribed regimen in these high risk patients with
CKD and AF undergoing PCI is DAPT. Patients on TT had similar rates of 1-year
MACE but more bleeding compared to those given DAPT.B140 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT AbstTCT-477
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Background: Elderly patients with atrial ﬁbrillation (AF) undergoing percutaneous
coronary intervention (PCI) are at an increased risk for bleeding and ischemic com-
plications. Optimum antithrombotic therapy in this group is controversial and
challenging.
Methods: Among 859 patients from the AVIATOR (Antithrombotic strategy vari-
ability in AF and obstructive coronary disease) registry who underwent PCI, 387
patients with age  75 were selected for this analysis. At discharge, these patients
were stratiﬁed into two groups: those receiving dual antiplatelet therapy (DAPT;
aspirin plus clopidogrel), and those receiving triple therapy (TT; DAPT plus warfarin).
Major adverse cardiovascular events (MACE) and bleeding rates in these antith-
rombotic groups were studied after one year.
Results: The mean age of patients who received DAPT was 814 years, whereas
those on TT had a mean age of 803 years. Patients receiving DAPT (n¼203, 52.5%)
were more likely to have a history of bleeding and infarction, while those on TT
(n¼184, 47.5%) had a past history of stroke. The 1-year MACE (15.7% vs 12.2%, HR
0.82, p¼0.548, for DAPT vs TT, respectively) and bleeding (9.4% vs 12.1%, HR
1.25, p¼0.413, for DAPT vs TT, respectively) rates were similar between the two
groups.
Conclusions: In contrast to consensus statements, elderly patients with AF under-
going PCI are most frequently treated with DAPT. Bleeding and ischemic compli-
cations remain substantial in this cohort irrespective of treatment.TCT-478
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Background: Development of deep venous thrombosis (DVT) in the setting of cancer
portends a poor prognosis. Low molecular weight heparins ( LMWH) are considered
the standard of care due to their superiority over warfarin. Additionally warfarin
resistance is common in cancer patients. The subcutaneous administration of LMWH
on a chronic basis is cumbersome and inconvenient. New oral anticoagulants (NOAC)
are promising drugs which can simplify long term care of cancer patients with DVT.
However little is known on their efﬁcacy in this setting. We therefore sought to
evaluate the role of NOAC in patients with cancer- related lower extremity (LE) DVT
who received rivaroxaban and apixaban following percutaneous endovenous inter-
vention (PEVI).
Methods: PEVI was performed in 50 patients with cancer who had developed
extensive symptomatic LE DVT. It was bilateral in 18 patients (36%). At the time of
DVT, 15 patients (30%) were on warfarin of whom 7 had therapeutic INR (64%).
PEVI was performed within 235 hours of admission. All patients received heparin
which was stopped after completion of PEVI. Rivaroxaban was initiated at 20 mg
daily and apixaban at 5 mg twice daily, 2 hours after PEVI, and continued indeﬁnitely.
Warfarin was stopped in all. The mean follow up was 154 months. The patients were
evaluated for mortality, recurrent VTE and bleeding during this period.racts/Pharmacotherapy - Chronic anticoagulants (warfarin and newer agents)
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: There were 5 deaths due to cancer at follow-up.There was no bleeding or
recurrent VTE in any patient. All patients tolerated the anticoagulation regimen. The
mean duration of hospitalization was 334 hours.
Conclusions: In patients with cancer associated DVT, Treatment with NOAC
following PEVI is highly safe and effective. It leads to shorter hospitalization
and no early or late bleeding or recurrent VTE. Patient satisfaction is higher as
the inconveniences associated with long term subcutaneous anticoagulation are
eliminated.Pharmacotherapy - Aspirin, Thienopyridines and other
Platelet Inhibitors
Washington Convention Center, Lower Level, Hall A
Saturday, September 13, 2014, 5:00 PM–7:00 PM
Abstract nos: 479-506
TCT-479
The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes is
Conﬁned to the First 30 days After PCI: Results from the Multicenter
ADAPT-DES Study
Ajay J. Kirtane1, Michael Rinaldi2, Bernhard Witzenbichler3, Giora Weisz4,
D. Christopher Metzger5, Timothy D. Henry6, David Cox7, Ernest L. Mazzaferri8,
Franz-Josef Neumann9, Ke Xu10, Akiko Maehara11, Philippe Genereux12,
Roxana Mehran13, Gregg W. Stone14
1Columbia University / Cardiovascular Research Foundation, New York, United
States, 2Sanger Heart and Vascular Institute, Carolinas HealthCare System,
Charlotte, United States, 3Charité Campus Benjamin Franklin, Berlin, Germany,
4Shaare Zedek Medical Center, Jerusalem, Israel, 5Wellmont CVA Heart Institute,
Kingsport, United States, 6Cedars-Sinai Medical Center, Los Angeles, CA, 7lehigh
valley hospital, Bethlehem, USA, 8Ohio State University, Dublin, OH, 9Universitaets-
Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany, 10Cardiovascular
Research Foundation, New York, NY, 11Cardiovascular Reserach Foundation and
Columbia University Medical Center, New York, United States, 12Columbia
University Medical Center, New York, 13Mount Sinai Hospital, New York, United
States, 14Columbia University Medical Center and the Cardiovascular Research
Foundation, New York, United States
Background: The incidence of stent thrombosis (ST) after percutaneous coronary
intervention (PCI) is higher among patients with acute coronary syndromes (ACS)
compared with stable ischemic heart disease. Whether this incremental increase in the
risk of ST is constant over the time after PCI is unknown.
Methods: The ADAPT-DES registry prospectively enrolled 8,582 patients with broad
inclusion criteria undergoing successful PCI with drug-eluting stents (DES). All pa-
tients underwent on-treatment platelet function testing using the VerifyNow assay. We
examined adjudicated ST outcomes at prespeciﬁed times following PCI among pa-
tients presenting with ACS with myocardial infarction (MI, n¼2063), ACS with
unstable angina (UA) alone (n¼2370), and no ACS (n¼4149).
Results: Patients with MI had the highest platelet reactivity units (PRU): mean 199
vs. 189 for UA vs. 182 for no ACS (p< 0.0001 for trend); the incidence of high
platelet reactivity deﬁned as PRU>208 was 48.0%, 43.3%, and 39.8%, respectively.
Correspondingly higher rates of 2-year deﬁnite/probable ST were observed among
patients with MI (1.75% vs. 1.13% for UA vs. 0.80% for no ACS, p¼0.003).
However, the increased incremental risk of ST among MI and UA patients was
conﬁned to the early period (ﬁrst 30 days after PCI: 0.98% vs. 0.42% vs. 0.22%,
p¼0.0002). The rates of late and very late ST were not signiﬁcantly different among
the 3 groups (Table).
Conclusions: Among patients undergoing successful DES implantation, the
increased ST risk conferred by the acuity of clinical presentation was conﬁned to
the ﬁrst 30 days after PCI and corresponded with increased on-treatment platelet
reactivity.ACS with
MI
Unstable Angina (ACS
without MI)
No
ACS
p for
trend
Overall ST 1.75% 1.13% 0.80% 0.003
Early ST (0-30
d)
0.98% 0.42% 0.22% <0.001
Late ST (31 d-1
yr)
0.55% 0.48% 0.30% 0.28
Very Late ST
(>1 yr)
0.27% 0.23% 0.31% 0.83
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Background: Patients sustaining Acute Coronary Syndromes (ACS) despite chronic
aspirin treatment, suffer from worse prognosis as compared to aspirin naïve pa-
tients. Despite growing use of clopidogrel, data regarding the characteristics and
prognostic signiﬁcance of patients with chronic use of clopidogrel sustaining ACS
is limited.
Methods: 5386 consecutive ACS patients who were drawn from the 2008, 2010,
2013 ACS Israeli survey(ACSIS)were characterized and followed-up for 30 days.
For the purpose of this study major adverse cardiac and cerebrovascular event
(MACCE) was deﬁned as death, re-myocardial infarction (MI), stroke and urgent
revascularization.
Results: Out of 5386 patients, 680 (12.6%) were treated with clopidogrel prior to
the index ACS. They were older (6612 vs. 6313 p< 0.01) and suffered more
from diabetes mellitus, hypertension, dyslipidemia as well as prior cardiovascular
history, including prior MI, revascularization, coronary artery bypass graft and
stroke, although, they were less likely to present with ST elevation MI (21% vs.
45%; p < 0.001). Nevertheless, they had more than 2 fold higher incidence of in
hospital stent thrombosis (1.6 % vs. 0.6 %, respectively, p ¼0.006) and stent
thrombosis at 30 days follow-up (2.2% vs. 1.0 %, respectively, p¼0.007). MACCE
rate at 30 days was also higher among chronic clopidogrel treatment patients [15.9
(12.3%) vs. 84 (9.4%), p< 0.01]. Multivariate log regression model analysis showed
that chronic clopidogrel treatment was independent predictors of stent thrombosis
[OR¼2.6 (95%CI 1.2-5.6)].
Conclusions: ACS patients with chronic clopidogrel treatment are at higher risk for in
hospital and 30 days stent thrombosis as well as worse prognosis at 30 days.
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Background: Current guidelines recommend prolonged dual antiplatelet therapy
(DAPT) consisting of aspirin and a thienopyridine for 12 months after drug-eluting
stent implantation. However, prolonged DAPT is associated with bleeding compli-
cations, and patient compliance and cost can be a barrier. Endeavor zotarolimus-
eluting stent (E-ZES) has demonstrated strong safety in short duration DAPT (3
months) analyses but no previous study randomized E-ZES patients to short and
prolonged DAPT.
Methods: Optimized Duration of Clopidogrel Therapy Following Treatment With
the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice
(OPTIMIZE) is an open-label, active-controlled, noninferiority study that random-
ized patients after percutaneous coronary intervention (PCI) 1:1 to 3 or 12 months
of DAPT consisting of aspirin (100-200 mg daily) and clopidogrel (75 mg daily).
Aspirin was prescribed indeﬁnitely. Eligible patients were those with stable coronary
artery disease or history of low-risk acute coronary syndrome undergoing PCI
with E-ZES. A total of 3119 patients in 33 sites in Brazil between April 2010 and
March 2012 were enrolled and randomized to 3 months (n¼ 1563) or 12 months of
DAPT (n¼ 1556). Patients have been followed to 2 years. At 12 months, 3 months
of DAPT was noninferior to 12 months for the composite of death, myocardial
infarction, stroke, or major bleeding, without a signiﬁcant increase in stent
thrombosis.
Results: Two year clinical results will be reported at TCT 2014.
Conclusions: This is the ﬁrst presentation of long-term results in a randomized study
of short (3-month) vs. long-term (12-month) DAPT usage after PCI implantation.rmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors B141
